Cited by 540RNA Interference and Gene DeliveryCRISPR and Genetic EngineeringNanoparticle-Based Drug Delivery

The DOI matches its Crossref record; 44 of the 45 references it cites were found in a registry or an index.

Non‐Viral CRISPR/Cas Gene Editing In Vitro and In Vivo Enabled by Synthetic Nanoparticle Co‐Delivery of Cas9 mRNA and sgRNA

Open access

Miller, Jason B., Zhang, Shuyuan, Kos, Petra, Xiong, Hu, Zhou, Kejin, Perelman, Sofya S., Zhu, Hao, Siegwart, Daniel J.·2017·Angewandte Chemie International Edition

DOI 10.1002/anie.201610209PMC PMC5521011

Open this paper in CoChat — free account

Abstract

CRISPR/Cas is a revolutionary gene editing technology with wide‐ranging utility. The safe, non‐viral delivery of CRISPR/Cas components would greatly improve future therapeutic utility. We report the synthesis and development of zwitterionic amino lipids (ZALs) that are uniquely able to (co)deliver long RNAs including Cas9 mRNA and sgRNAs. ZAL nanoparticle (ZNP) delivery of low sgRNA doses (15 n m ) reduces protein expression by >90 % in cells. In contrast to transient therapies (such as RNAi), we show that ZNP delivery of sgRNA enables permanent DNA editing with an indefinitely sustained 95 % decrease in protein expression. ZNP delivery of mRNA results in high protein expression at low doses in vitro (<600 pM) and in vivo (1 mg kg −1 ). Intravenous co‐delivery of Cas9 mRNA and sgLoxP induced expression of floxed tdTomato in the liver, kidneys, and lungs of engineered mice. ZNPs provide a chemical guide for rational design of long RNA carriers, and represent a promising step towards improving the safety and utility of gene editing.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1002/anie.201610209

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Genome engineering using the CRISPR-Cas9 system
Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013) · Nature Protocols · doi:10.1038/nprot.2013.143 · Cited by 11,133
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
CRISPR-Cas systems for editing, regulating and targeting genomes
Sander, J. D., & Joung, J. K. (2014) · Nature Biotechnology · doi:10.1038/nbt.2842 · Cited by 3,153
CRISPR-Cas9 Knockin Mice for Genome Editing and Cancer Modeling
Platt, R. J., Chen, S., Zhou, Y., Yim, M. J., Swiech, L., Kempton, H. R., Dahlman, J. E., Parnas, O., Eisenhaure, T. M., Jovanovic, M., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.014 · Cited by 2,001
Rational design of cationic lipids for siRNA delivery
Semple, S. C., Akinc, A., Chen, J., Sandhu, A. P., Mui, B. L., Cho, C. K., Sah, D. W. Y., Stebbing, D., Crosley, E. J., Yaworski, E., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1602 · Cited by 1,822
Delivery materials for siRNA therapeutics
Kanasty, R., Dorkin, J. R., Vegas, A., & Anderson, D. (2013) · Nature Materials · doi:10.1038/nmat3765 · Cited by 1,800
Image-based analysis of lipid nanoparticle–mediated siRNA delivery, intracellular trafficking and endosomal escape
Gilleron, J., Querbes, W., Zeigerer, A., Borodovsky, A., Marsico, G., Schubert, U., Manygoats, K., Seifert, S., Andree, C., Stöter, M., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2612 · Cited by 1,681
Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo
Zuris, J. A., Thompson, D. B., Shu, Y., Guilinger, J. P., Bessen, J. L., Hu, J. H., Maeder, M. L., Joung, J. K., Chen, Z.-Y., & Liu, D. R. (2015) · Nature Biotechnology · doi:10.1038/nbt.3081 · Cited by 1,460

Flagged first, then by citations

Show all 45 references

1 of the 45 references couldn’t be matched to a known paper.

Sorted by citations

Items 201–300 of 540

Naturally Derived Membrane Lipids Impact Nanoparticle-Based Messenger RNA Delivery
Kim, J., Jozic, A., & Sahay, G. (2020) · Cellular and Molecular Bioengineering · doi:10.1007/s12195-020-00619-y · Cited by 61
CRISPR/Cas12a Powered DNA Framework‐Supported Electrochemical Biosensing Platform for Ultrasensitive Nucleic Acid Analysis
Su, J., Ke, Y., Maboyi, N., Zhi, X., Yan, S., Li, F., Zhao, B., Jia, X., Song, S., & Ding, X. (2021) · Small Methods · doi:10.1002/smtd.202100935 · Cited by 63
CRISPR-delivery particles targeting nuclear receptor–interacting protein 1 (Nrip1) in adipose cells to enhance energy expenditure
Shen, Y., Cohen, J. L., Nicoloro, S. M. C., Kelly, M., Yenilmez, B., Henriques, F. D. S., Tsagkaraki, E., Edwards, Y. J. K., Hu, X., Friedline, R. H., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.004554 · Cited by 61
Delivery Approaches for Therapeutic Genome Editing and Challenges
Ates, I., Rathbone, T., Stuart, C., Bridges, P. H., & Cottle, R. N. (2020) · Genes · doi:10.3390/genes11101113 · Cited by 63
Evolution and Application of Genome Editing Techniques for Achieving Food and Nutritional Security
Fiaz, S., Ahmar, S., Saeed, S., Riaz, A., Mora, F., & Jung, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115585 · Cited by 61
Principles of lipid nanoparticle design for mRNA delivery
Zhang, Y., Zhang, X., Gao, Y., & Liu, S. (2024) · BMEMat · doi:10.1002/bmm2.12116 · Cited by 62
CRISPR–Cas9 delivery strategies for the modulation of immune and non-immune cells
Alsaiari, S. K., Eshaghi, B., Du, B., Kanelli, M., Li, G., Wu, X., Zhang, L., Chaddah, M., Lau, A., Yang, X., et al. (2024) · Nature Reviews Materials · doi:10.1038/s41578-024-00725-7 · Cited by 63
Nanobiomaterial vectors for improving gene editing and gene therapy
Hu, S. W., Ding, T., Tang, H., Guo, H., Cui, W., & Shu, Y. (2023) · Materials Today · doi:10.1016/j.mattod.2023.04.011 · Cited by 58
Targeting materials and strategies for RNA delivery
Lin, L., Su, K., Cheng, Q., & Liu, S. (2023) · Theranostics · doi:10.7150/thno.87316 · Cited by 61
Amplification-free miRNA detection with CRISPR/Cas12a system based on fragment complementary activation strategy
Zhao, S., Zhang, Q., Luo, R., Sun, J., Zhu, C., Zhou, D., & Gong, X. (2024) · Chemical Science · doi:10.1039/d4sc05647g · Cited by 58
Progress and challenges towards CRISPR/Cas clinical translation
Rosenblum, D., Gutkin, A., Dammes, N., & Peer, D. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.004 · Cited by 61
Lipid- and polymer-based nanoparticle systems for the delivery of CRISPR/Cas9
Ashok, B., Peppas, N. A., & Wechsler, M. E. (2021) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2021.102728 · Cited by 62
mRNA, a Revolution in Biomedicine
Baptista, B., Carapito, R., Laroui, N., Pichon, C., & de Sousa, F. P. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13122090 · Cited by 61
Nanoparticles-mediated CRISPR-Cas9 gene therapy in inherited retinal diseases: applications, challenges, and emerging opportunities
Chien, Y., Hsiao, Y., Chou, S., Lin, T.-Y., Yarmishyn, A. A., Lai, W., Lee, M., Lin, Y., Lin, T.-W., Hwang, D., et al. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01717-x · Cited by 59
Combinational application of metal–organic frameworks‐based nanozyme and nucleic acid delivery in cancer therapy
Ni, D., Lin, J., Zhang, N., Li, S., Xue, Y., Wang, Z., Liu, Q., Liu, K., Zhang, H., Zhao, Y., et al. (2022) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1773 · Cited by 55
Delivery of nucleic acid based genome editing platforms via lipid nanoparticles: Clinical applications
Masarwy, R., Stotsky‐Oterin, L., Elisha, A., Hazan‐Halevy, I., & Peer, D. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115359 · Cited by 59
Single-Base Resolution: Increasing the Specificity of the CRISPR-Cas System in Gene Editing
Rabinowitz, R., & Offen, D. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.11.009 · Cited by 58
Intelligent nanotherapeutic strategies for the delivery of CRISPR system
Chen, C., Zhong, W., Du, S., Li, Y., Zeng, Y., Liu, K., Yang, J., Guan, X., & Han, X. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.12.013 · Cited by 54
Nano-bio interactions in mRNA nanomedicine: Challenges and opportunities for targeted mRNA delivery
Saiding, Q., Zhang, Z., Chen, S., Xiao, F., Chen, Y., Li, Y., Zhen, X., Khan, M. M., Chen, W., Koo, S., et al. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115116 · Cited by 59
Lipid Nanoparticles for Delivery of CRISPR Gene Editing Components
Wu, F., Li, N., Xiao, Y., Palanki, R., Yamagata, H. M., Mitchell, M. J., & Han, X. (2025) · Small Methods · doi:10.1002/smtd.202401632 · Cited by 64
Hematopoietic Stem Cell Gene-Addition/Editing Therapy in Sickle Cell Disease
Germino-Watnick, P., Hinds, M., Le, A., Chu, R., Liu, X., & Uchida, N. (2022) · Cells · doi:10.3390/cells11111843 · Cited by 63
Biomaterials as Tools to Decode Immunity
Eppler, H. B., & Jewell, C. M. (2019) · Advanced Materials · doi:10.1002/adma.201903367 · Cited by 53
Approach for in vivo delivery of CRISPR/Cas system: a recent update and future prospect
Chuang, Y.-F., Phipps, A. J., Lin, F., Hecht, V. F. G., Hewitt, A. W., Wang, P., & Liu, G. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03725-2 · Cited by 53
A review on nanotechnology and its applications on Fluid Flow in agriculture and water recourses
Hamad, H. T., Al-Sharify, Z. T., Al-Najjar, S. Z., & Gadooa, Z. A. (2020) · IOP Conference Series Materials Science and Engineering · doi:10.1088/1757-899x/870/1/012038 · Cited by 52
A Combinatorial Library of Biodegradable Lipid Nanoparticles Preferentially Deliver mRNA into Tumor Cells to Block Mutant RAS Signaling
Cai, W., Luo, T., Chen, X., Mao, L., & Wang, M. (2022) · Advanced Functional Materials · doi:10.1002/adfm.202204947 · Cited by 53
Modulating intracellular pathways to improve non-viral delivery of RNA therapeutics
de Vyver, T. V., Smedt, S. C. D., & Raemdonck, K. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114041 · Cited by 51
High‐Precision Synthesis of RNA‐Loaded Lipid Nanoparticles for Biomedical Applications
Seo, H., Jeon, L., Kwon, J., & Lee, H. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202203033 · Cited by 54
Systemic delivery of CRISPR/Cas9 to hepatic tumors for cancer treatment using altered tropism of lentiviral vector
Lee, S., Kim, Y.-Y., & Ahn, H. J. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120793 · Cited by 50
Cell Subtypes Within the Liver Microenvironment Differentially Interact with Lipid Nanoparticles
Sago, C. D., Krupczak, B. R., Lokugamage, M. P., Gan, Z., & Dahlman, J. E. (2019) · Cellular and Molecular Bioengineering · doi:10.1007/s12195-019-00573-4 · Cited by 53
Strategies for the CRISPR-Based Therapeutics
Li, B., Niu, Y., Ji, W., & Dong, Y. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.11.006 · Cited by 52
Gene Delivery to the Skin – How Far Have We Come?
Ain, Q. U., Campos, E. V. R., Huynh, A., Witzigmann, D., & Hedtrich, S. (2020) · Trends in biotechnology · doi:10.1016/j.tibtech.2020.07.012 · Cited by 51
PLGA-Nanoparticles for Intracellular Delivery of the CRISPR-Complex to Elevate Fetal Globin Expression in Erythroid Cells
Cruz, L. J., van Dijk, T., Vepris, O., Li, T. M. W. Y., Schomann, T., Baldazzi, F., Kurita, R., Nakamura, Y., Grosveld, F. G., Philipsen, S., et al. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120580 · Cited by 51
Spinal cord injury target-immunotherapy with TNF-α autoregulated and feedback-controlled human umbilical cord mesenchymal stem cell derived exosomes remodelled by CRISPR/Cas9 plasmid
Wang, B., Chang, M., Zhang, R., Wo, J., Wu, B., Zhang, H., Zhou, Z., Li, Z., Zhang, F., Zhong, C. F., et al. (2021) · Biomaterials Advances · doi:10.1016/j.msec.2021.112624 · Cited by 49
Nanotechnology: an Emerging Hope in Crop Improvement
(2021) · Letters in Applied NanoBioScience · doi:10.33263/lianbs104.27842803 · Cited by 49
The potential for targeted rewriting of epigenetic marks in COPD as a new therapeutic approach
Wu, D., Song, J., Bartel, S., Krauss‐Etschmann, S., Rots, M. G., & Hylkema, M. N. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.08.007 · Cited by 50
DNA-free gene editing in plants: a brief overview
Tsanova, T., Stefanova, L., Topalova, L., Atanasov, A. T., & Pantchev, I. Y. (2020) · Biotechnology & Biotechnological Equipment · doi:10.1080/13102818.2020.1858159 · Cited by 48
Progress and Perspective of CRISPR‐Cas9 Technology in Translational Medicine
Zheng, R., Zhang, L., Parvin, R., Su, L., Chi, J., Shi, K., Ye, F., & Huang, X. (2023) · Advanced Science · doi:10.1002/advs.202300195 · Cited by 56
Nanoparticle depots for controlled and sustained gene delivery
Li, Z., Ho, W., Bai, X., Li, F., Chen, Y.-J., Zhang, X., & Xu, X. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.03.021 · Cited by 49
A Nucleic Acid/Gold Nanorod-Based Nanoplatform for Targeted Gene Editing and Combined Tumor Therapy
Tang, W., Han, L., Lu, X., Wang, Z., Liu, F., Li, Y., Liu, S., Liu, S., Tian, R., Liu, J., et al. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c02122 · Cited by 47
Stimulus-Responsive Smart Nanoparticles-Based CRISPR-Cas Delivery for Therapeutic Genome Editing
Naeem, M., Hoque, M. Z., Ovais, M., Basheer, C., & Ahmad, I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222011300 · Cited by 51
Nanomaterials for Plant Disease Diagnosis and Treatment: A Review
Carrillo-López, L. M., Villanueva-Verduzco, C., Villanueva-Sánchez, E., Fajardo-Franco, M. L., Aguilar-Tlatelpa, M., Ventura‐Aguilar, R. I., & Soto‐Hernández, M. (2024) · Plants · doi:10.3390/plants13182634 · Cited by 48
Nucleic Acid Delivery by Solid Lipid Nanoparticles Containing Switchable Lipids: Plasmid DNA vs. Messenger RNA
Gómez-Aguado, I., Rodríguez-Castejón, J., Vicente-Pascual, M., Rodríguez‐Gascón, A., del Pozo‐Rodríguez, A., & Solinís, M. Á. (2020) · Molecules · doi:10.3390/molecules25245995 · Cited by 49
Dynamic mRNA polyplexes benefit from bioreducible cleavage sites for in vitro and in vivo transfer
Levačić, A. K., Berger, S., Müller, J., Wegner, A., Lächelt, U., Dohmen, C., Rudolph, C., & Wagner, E. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.09.016 · Cited by 47
mRNA delivery in cancer immunotherapy
Zhong, Y., Du, S., & Dong, Y. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.03.001 · Cited by 49
Development of delivery strategies for CRISPR‐Cas9 genome editing
Liu, Q., Yang, J., Xing, Y., Zhao, Y., & Liu, Y. (2023) · BMEMat · doi:10.1002/bmm2.12025 · Cited by 47
New approaches to moderate CRISPR-Cas9 activity: Addressing issues of cellular uptake and endosomal escape
van Hees, M., Slott, S., Hansen, A. H., Kim, H. S., Ji, H. P., & Astakhova, K. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.06.003 · Cited by 47
Lipid-based nanocarrier mediated CRISPR/Cas9 delivery for cancer therapy
Aziz, A., Rehman, U., Sheikh, A., Abourehab, M. A. S., & Kesharwani, P. (2022) · Journal of Biomaterials Science Polymer Edition · doi:10.1080/09205063.2022.2121592 · Cited by 47
Innovative Strategies of Reprogramming Immune System Cells by Targeting CRISPR/Cas9-Based Genome-Editing Tools: A New Era of Cancer Management
Allemailem, K. S., Alsahli, M. A., Almatroudi, A., Alrumaihi, F., Abdulmonem, W. A., Moawad, A. A., Alwanian, W. M., Almansour, N. M., Rahmani, A. H., & Khan, A. A. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s424872 · Cited by 49
Understanding structural and molecular properties of complexes of nucleobases and Au13 golden nanocluster by DFT calculations and DFT-MD simulation
Hashemkhani, G., & Ganji, M. D. (2021) · Scientific Reports · doi:10.1038/s41598-020-80161-z · Cited by 44
Calcium-based nanomaterials and their interrelation with chitosan: optimization for pCRISPR delivery
Rabiee, N., Bagherzadeh, M., Ghadiri, A. M., Kiani, M., Ahmadi, S., Jajarmi, V., Fatahi, Y., Aldhaher, A., Tahriri, M., Webster, T. J., et al. (2021) · Journal of nanostructure in chemistry · doi:10.1007/s40097-021-00446-1 · Cited by 43
The CRISPR/Cas9 system: Their delivery, in vivo and ex vivo applications and clinical development by startups
Song, M. (2017) · Biotechnology Progress · doi:10.1002/btpr.2484 · Cited by 46
Lipid‐Modified Aminoglycosides for mRNA Delivery to the Liver
Yu, X., Liu, S., Cheng, Q., Wei, T., Lee, S. M., Zhang, D., & Siegwart, D. J. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.201901487 · Cited by 46
Self-citation
Appropriate Delivery of the CRISPR/Cas9 System through the Nonlysosomal Route: Application for Therapeutic Gene Editing
Yin, H., Yuan, X., Luo, L., Lu, Y., Qin, B., Zhang, J., Shi, Y., Zhu, C., Yang, J., Li, X., et al. (2020) · Advanced Science · doi:10.1002/advs.201903381 · Cited by 42
Development of Cationic Quaternary Ammonium Sulfonamide Amino Lipids for Nucleic Acid Delivery
Miller, J. B., Kós, P., Tieu, V., Zhou, K., & Siegwart, D. J. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b15982 · Cited by 43
Self-citation
The rapidly evolving state of gene therapy
Gruntman, A. M., & Flotte, T. R. (2018) · The FASEB Journal · doi:10.1096/fj.201700982r · Cited by 42
Lipid-mRNA Nanoparticle Designed to Enhance Intracellular Delivery Mediated by Shock Waves
Zhang, J., Shrivastava, S., Cleveland, R. O., & Rabbitts, T. H. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b21398 · Cited by 43
Advances of Nanoparticles for Leukemia Treatment
Shen, J., Lü, Z., Wang, J., Zhang, T., Yang, H. J., Li, Y., Liu, G., & Zhang, X. (2020) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.0c01040 · Cited by 41
Membrane-Specific Binding of 4 nm Lipid Nanoparticles Mediated by an Entropy-Driven Interaction Mechanism
Ou, L., Chen, H., Yuan, B., & Yang, K. (2022) · ACS Nano · doi:10.1021/acsnano.2c04774 · Cited by 42
Current strategies employed in the manipulation of gene expression for clinical purposes
Tsai, H., Pietrobon, V., Peng, M., Wang, S., Zhao, L., Marincola, F. M., & Cai, Q. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03747-3 · Cited by 48
CRISPR/Cas9: at the cutting edge of hepatology
Pankowicz, F. P., Jarrett, K. E., Lagor, W. R., & Bissig, K. (2017) · Gut · doi:10.1136/gutjnl-2016-313565 · Cited by 43
CRISPR/Cas9 Delivery Potentials in Alzheimer’s Disease Management: A Mini Review
Hanafy, A. S., Schoch, S., & Lamprecht, A. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12090801 · Cited by 43
ZnAl nano layered double hydroxides for dual functional CRISPR/Cas9 delivery and enhanced green fluorescence protein biosensor
Rabiee, N., Bagherzadeh, M., Ghadiri, A. M., Salehi, G., Fatahi, Y., & Dinarvand, R. (2020) · Scientific Reports · doi:10.1038/s41598-020-77809-1 · Cited by 43
Gene editing with CRISPR-Cas12a guides possessing ribose-modified pseudoknot handles
Ageely, E. A., Chilamkurthy, R., Jana, S. K., Abdullahu, L., O’Reilly, D., Jensik, P. J., Damha, M. J., & Gagnon, K. T. (2021) · Nature Communications · doi:10.1038/s41467-021-26989-z · Cited by 40
Virus Spike and Membrane-Lytic Mimicking Nanoparticles for High Cell Binding and Superior Endosomal Escape
Liu, S., Yang, J., Jia, H., Zhou, H., Chen, J., & Guo, T. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b06934 · Cited by 40
Design of synthetic materials for intracellular delivery of RNAs: From siRNA-mediated gene silencing to CRISPR/Cas gene editing
Miller, J. B., & Siegwart, D. J. (2018) · Nano Research · doi:10.1007/s12274-018-2099-4 · Cited by 41
Self-citation
Emerging Biomimetic Drug Delivery Nanoparticles Inspired by Extracellular Vesicles
Sundaram, V., & Aryal, S. (2025) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.70025 · Cited by 44
Therapeutic applications of CRISPR/Cas9 in breast cancer and delivery potential of gold nanomaterials
Padayachee, J., & Singh, M. (2020) · Nanobiomedicine · doi:10.1177/1849543520983196 · Cited by 39
mRNA‐Loaded Lipid‐Like Nanoparticles for Liver Base Editing Via the Optimization of Central Composite Design
Zheng, Q., Qin, F., Luo, R., Jin, C., Huang, H., He, X., Xiao, W., Guo, M., Yang, S., He, S., et al. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202011068 · Cited by 39
Engineering a CRISPR interference system targeting AcrAB-TolC efflux pump to prevent multidrug resistance development in Escherichia coli
Wan, X., Li, Q., Olsen, R. H., Meng, H., Zhang, Z., Wang, J., Zheng, H., Li, L., & Shi, L. (2022) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkac166 · Cited by 38
CRISPR/Cas systems to overcome challenges in developing the next generation of T cells for cancer therapy
Huang, D., Miller, M., Ashok, B., Jain, S., & Peppas, N. A. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.015 · Cited by 38
Traceable Nano‐Biohybrid Complexes by One‐Step Synthesis as CRISPR‐Chem Vectors for Neurodegenerative Diseases Synergistic Treatment
Shen, J., Lü, Z., Wang, J., Hao, Q., Ji, W., Wu, Y., Peng, H., Zhao, R., Yang, J., Li, Y., et al. (2021) · Advanced Materials · doi:10.1002/adma.202101993 · Cited by 38
Revolutionising healing: Gene Editing's breakthrough against sickle cell disease
Dimitrievska, M., Bansal, D., Vitale, M., Strouboulis, J., Miccio, A., Nicolaides, K. H., Hoss, S. E., Shangaris, P., & Jackow, J. (2024) · Blood Reviews · doi:10.1016/j.blre.2024.101185 · Cited by 41
Combination of [12]aneN3 and Triphenylamine-Benzylideneimidazolone as Nonviral Gene Vectors with Two-Photon and AIE Properties
Liu, M., Ma, L., Liu, X., Liu, J., Lu, Z., Liu, R., & He, L. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b15169 · Cited by 37
Delivery of genome editing tools: A promising strategy for HPV-related cervical malignancy therapy
Aghamiri, S., Talaei, S., Roshanzamiri, S., Zandsalimi, F., Fazeli, E., Aliyu, M., Avarvand, O. K., Ebrahimi, Z., Keshavarz‐Fathi, M., & Ghanbarian, H. (2020) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2020.1747429 · Cited by 37
CRISPR/Cas9 gene editing therapies for cystic fibrosis
Graham, C., & Hart, S. L. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1869208 · Cited by 39
CRISPR/Cas-Dependent and Nuclease-Free In Vivo Therapeutic Gene Editing
Dasgupta, I., Flotte, T. R., & Keeler, A. M. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.013 · Cited by 38
In Vivo Prime Editing by Lipid Nanoparticle Co-Delivery of Chemically Modified pegRNA and Prime Editor mRNA
Chen, Z., Kelly, K., Cheng, H., Dong, X., Hedger, A. K., Li, L., Sontheimer, E. J., & Watts, J. K. (2023) · GEN Biotechnology · doi:10.1089/genbio.2023.0045 · Cited by 37
Advancing cancer gene therapy: the emerging role of nanoparticle delivery systems
Wang, M., Liu, H., Huang, J., Cai, T., Xu, Z. P., & Zhang, L. L. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03433-8 · Cited by 37
Gene Targeting of HPV18 E6 and E7 Synchronously by Nonviral Transfection of CRISPR/Cas9 System in Cervical Cancer
Ling, K., Yang, L., Yang, N., Chen, M., Wang, Y., Shi, L., Li, Y., Jiang, L., Yan, P., & Liang, Z. (2020) · Human Gene Therapy · doi:10.1089/hum.2019.246 · Cited by 35
mRNA delivery via non-viral carriers for biomedical applications
Shuai, Q., Zhu, F., Zhao, M., & Yan, Y. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.121020 · Cited by 35
Development of nucleic acid medicines based on chemical technology
Kawamoto, Y., Wu, Y., Takahashi, Y., & Takakura, Y. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114872 · Cited by 34
Nanomedicine for Cystic Fibrosis
Ong, V., Mei, V., Cao, L. S., Lee, K., & Chung, E. J. (2019) · SLAS TECHNOLOGY · doi:10.1177/2472630318824334 · Cited by 34
A Genome-Editing Nanomachine Constructed with a Clustered Regularly Interspaced Short Palindromic Repeats System and Activated by Near-Infrared Illumination
Peng, H., Le, C., Wu, J., Li, X., Zhang, H., & Le, X. C. (2020) · ACS Nano · doi:10.1021/acsnano.9b05276 · Cited by 34
Zwitterionic materials for nucleic acid delivery and therapeutic applications
He, S., & Liu, S. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.12.017 · Cited by 33
Synthetic Vehicles for Encapsulation and Delivery of CRISPR/Cas9 Gene Editing Machinery
Carboni, V., Maaliki, C., Alyami, M., Alsaiari, S. K., & Khashab, N. M. (2019) · Advanced Therapeutics · doi:10.1002/adtp.201800085 · Cited by 34
Sustained release of PKR inhibitor C16 from mesoporous silica nanoparticles significantly enhances mRNA translation and anti-tumor vaccination
Zhang, W., Liu, Y., Chin, J. M., & Phua, K. K. L. (2021) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2021.03.011 · Cited by 33
Recent development of gene therapy for pancreatic cancer using non-viral nanovectors
Liu, Y., Wu, W., Wang, Y., Han, S., Yuan, Y., Huang, J., Shuai, X., & Peng, Z. M. (2021) · Biomaterials Science · doi:10.1039/d1bm00748c · Cited by 35
Challenges of CRISPR-Based Gene Editing in Primary T Cells
Rezalotfi, A., Fritz, L. V., Förster, R., & Bošnjak, B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031689 · Cited by 33
Techniques for investigating lncRNA transcript functions in neurodevelopment
Srinivas, T., Soares, E. S., & Guil, S. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02377-5 · Cited by 37
Shaping the future from the small scale: dry powder inhalation of CRISPR-Cas9 lipid nanoparticles for the treatment of lung diseases
Carneiro, S. P., Greco, A., Chiesa, E., Genta, I., & Merkel, O. M. (2023) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2023.2185220 · Cited by 33
Engineered CRISPR Systems for Next Generation Gene Therapies
Pineda, M., Moghadam, F., Ebrahimkhani, M. R., & Kiani, S. (2017) · ACS Synthetic Biology · doi:10.1021/acssynbio.7b00011 · Cited by 30
Mutation-Directed Therapeutics for Neurofibromatosis Type I
Leier, A., Bedwell, D. M., Chen, A. T., Dickson, G., Keeling, K. M., Kesterson, R. A., Korf, B. R., Marquez‐Lago, T. T., Müller, U. F., Popplewell, L. J., et al. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.04.012 · Cited by 32
Layer-by-Layer technique as a versatile tool for gene delivery applications
Linnik, D., Tarakanchikova, Y. V., Zyuzin, M. V., Lepik, K. V., Aerts, J. L., Sukhorukov, G. B., & Timin, A. S. (2021) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2021.1879790 · Cited by 33
A Systematic Study of Unsaturation in Lipid Nanoparticles Leads to Improved mRNA Transfection In Vivo
Lee, S. M., Cheng, Q., Yu, X., Liu, S., Johnson, L. T., & Siegwart, D. J. (2020) · Angewandte Chemie · doi:10.1002/ange.202013927 · Cited by 33
Self-citation
mRNA-based modalities for infectious disease management
Zhang, M., Hussain, A., Yang, H., Zhang, J., Liang, X., & Huang, Y. (2022) · Nano Research · doi:10.1007/s12274-022-4627-5 · Cited by 35
Multifunctional Vector for Delivery of Genome Editing Plasmid Targeting β-Catenin to Remodulate Cancer Cell Properties
He, X., Liu, B., Peng, Y., Zhuo, R., & Cheng, S. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b17481 · Cited by 31
Non-viral nanocarriers for CRISPR-Cas9 gene editing system delivery
Tang, X., Wang, Z., Zhang, Y., Mu, W., & Han, X. (2022) · Chemical Engineering Journal · doi:10.1016/j.cej.2022.135116 · Cited by 30
Nanodevices for the Efficient Codelivery of CRISPR-Cas9 Editing Machinery and an Entrapped Cargo: A Proposal for Dual Anti-Inflammatory Therapy
García‐Fernández, A., Vivo‐Llorca, G., Sancho, M., García-Jareño, A. B., Ramírez‐Jiménez, L., Barber‐Cano, E., Murguía, J. R., Orzáez, M., Sancenón, F., & Martínez‐Máñez, R. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14071495 · Cited by 31
Recent advances in nanocomposite-based delivery systems for targeted CRISPR/Cas delivery and therapeutic genetic manipulation
Ghani, M. W., Iqbal, A., Ghani, H., Bibi, S., Wang, Z., & Pei, R. (2023) · Journal of Materials Chemistry B · doi:10.1039/d2tb02610d · Cited by 32
Peptide and Aptamer Decorated Delivery System for Targeting Delivery of Cas9/sgRNA Plasmid To Mediate Antitumor Genome Editing
Liu, B., He, X., Xu, C., Ren, X., Zhuo, R., & Cheng, S. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b05772 · Cited by 30

Authors: Miller, J. B., Zhang, S., Kos, P., Xiong, H., Zhou, K., Perelman, S. S., Zhu, H., & Siegwart, D. J.
Affiliations: Harold C. Simmons Comprehensive Cancer Center (US)
The University of Texas Southwestern Medical Center (US)
University of Texas Southwestern Medical Center Simmons Comprehensive Cancer Center Department of Biochemistry Dallas TX 75390 USA
Corresponding author: Siegwart, Daniel J.
ORCID: Miller, Jason B.
Zhang, Shuyuan
Xiong, Hu
Perelman, Sofya S.
Zhu, Hao
Siegwart, Daniel J.
Venue: Angewandte Chemie International Edition
Publisher: Wiley
Published: 2016-12-16
Volume: 56
Issue: 4
Pages: 1059-1063
ISSN: 1433-7851 (ISSN-L)
1521-3773
DOI: 10.1002/anie.201610209
PMC: PMC5521011
OpenAlex: W2560987571
Cited by: 540
References: 45
Citations by year: 2026: 35 · 2025: 39 · 2024: 47 · 2023: 48 · 2022: 66 · 2021: 86 · 2020: 79 · 2019: 59 · 2018: 55 · 2017: 24 · 2016: 1
FWCI: 24.09
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Angewandte Chemie International Edition (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (R01CA190525)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
Keywords: CRISPR gene editing, lipid nanoparticles, Cas9 mRNA, single guide RNA, co-delivery, in vivo gene editing, loxP
MeSH terms: Gene Editing, RNA, Guide, CRISPR-Cas Systems, Lipids, RNA, Messenger, Molecular Structure, RNA, Guide, Kinetoplastida, Gene Transfer Techniques, Nanoparticles, CRISPR-Cas Systems

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Non‐Viral CRISPR/Cas Gene Editing In Vitro and In Vivo Enabled by Synthetic Nanoparticle Co‐Delivery of Cas9 mRNA and sgRNA

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks